Therefore, it is important to deepen the investigation of A2AR as a target for the development of existing or new agents targeting this axis, along with further testing of combinatorial strategies, which may be relevant in the search for pharmacological therapies for HD patients. The gene discussed is ADORA2A; the disease is Huntington disease.